View Post

New Study Shows a Decline in the Incidence of Recurrent Metastatic Breast Cancer Over Time but no Improvement in Survival

In In The News by Barbara Jacoby

From: prnewswire.com A retrospective analysis –  reported in the journal Breast Cancer Research and Treatment, by Judith Malmgren, PhD, and co-authors – studied 8292 women with stage I-III invasive breast cancer, 964 of whom (11.6%) were later diagnosed with recurrent metastatic breast cancer (rMBC). The authors found a significant decline in rMBC over time, but no increase in survival. Survival …

View Post

What happens when breast cancer metastasizes in the lungs?

In In The News by Barbara Jacoby

By: Jamie Eske From: medicalnewstoday.com Metastatic is a term that refers to cancer that has spread outside of the original area to a different place in the body. Metastatic breast cancer in the lungs refers to cancer that originally developed inside the breast tissue but has spread to the lungs. Breast cancer is the most common form of cancer among …

View Post

Fibrosis-targeting drugs may benefit patients with late-stage, metastatic breast cancer

In In The News by Barbara Jacoby

Source: massgeneral.org From: news-medical.net A Massachusetts General Hospital (MGH) research team has found that the overgrowth of connective called fibrosis may block the effectiveness of immunotherapies against metastatic breast cancer. Their report published in PNAS also finds that plerixafor, a drug approved to mobilize blood system stem cells in the treatment of lymphoma and multiple myeloma patients, can reduce fibrosis …

View Post

Fred Hutch researchers root out sleeping breast cancer cells to stop metastasis

In In The News by Barbara Jacoby

By: James Thorne From: geekwire.com Researchers at the Fred Hutchinson Cancer Research Center led by Dr. Cyrus Ghajar recently uncovered promising new science in the battle against metastatic breast cancer. Their findings, published today in Nature Cell Biology, show that it’s possible to destroy cancer cells that can hide for years in people’s bone marrow. Chemotherapy is often effective at …

View Post

Cancer: Drug fights formation of metastasis

In In The News by Barbara Jacoby

Source: University of Basel From: sciencedaily.com The most deadly aspect of breast cancer is metastasis. It spreads cancer cells throughout the body. Researchers at the University and the University Hospital of Basel have now discovered a substance that suppresses the formation of metastases. In the journal Cell, the team of molecular biologists, computational biologists, and clinicians reports on their interdisciplinary …

View Post

Athenex Announces Completion of Target Enrollment in the Oraxol Phase III Study

In Clinical Trials by Barbara Jacoby

By: GlobeNewswire From: nasdaq.com Athenex, Inc. (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that target enrollment of 360 patients in the Oraxol Phase III clinical trial in metastatic breast cancer has been achieved on schedule. Athenex also reaffirms that top line data from …

View Post

CTC Counts Hold Value in Therapy Selection for Metastatic Breast Cancer

In In The News by Barbara Jacoby

By: Tony Hagen From: targetedonc.com At the 2018 San Antonio Breast Cancer Symposium, data demonstrated that use of circulating tumor-cell (CTC) counts had strong value for selecting endocrine therapy compared to chemotherapy in patients with estrogen receptor–positive, HER2-negative metastatic breast cancer. A CTC cutoff value was used to determine first-line treatment in this double-arm, randomized trial. There was high concordance between clinician’s choice …

View Post

Oncology Venture receives positive feed-back from the FDA on approval pathway for LiPlaCis and DRP in the US

In Clinical Trials by Barbara Jacoby

From: ptcommunity.com Oncology Venture A/S (“OV” or the Company) today announced that the US Food and Drug Administration, FDA has responded positively on questions posed by the company in a Pre-IND/IDE package for the approval pathway for LiPlaCis® and its companion diagnostic DRP® – Drug Response Predictor – in metastatic breast cancer. Hørsholm, Denmark and Cambridge, MA, US, December 18, …

View Post

Herceptin Biosimilar Herzuma Approved for Certain Breast Cancer Indications

In In The News by Barbara Jacoby

By: Da Hee Han, PharmD From: empr.com Celltrion and Teva announced that the Food and Drug Administration (FDA) has approved Herzuma (trastuzumab-pkrb) injection, a new biosimilar to Herceptin (trastuzumab; Genentech) for certain HER2-overexpressing breast cancer indications. Patients should be selected for treatment based on an FDA-approved companion diagnostic for a trastuzumab product. Specifically, Herzuma is approved to treat: Adjuvant breast …